Big Pharma is not the only slow moving behemoth involved in the CRISPR/Cas9 revolution with a US team citing the gene editing tech as key to its efforts to resurrect the woolly mammoth.
Ancient nomadic kings’ love of life in the saddle did not hamper another of their favourite pastimes according to a study suggesting millions of Asian men are descended from just 11 fathers.
Did you know that throughout the nineteenth century, vaccination left a scar known as “the mark of the beast”? Or that parents believed vaccination would cause children to grow cows’ horns?
In an exclusive extract from her recent book On Immunity: An Innoculation, author Eula Biss describes her exploration of the social history and cultural myths surrounding vaccines.To be in with a chance of winning a copy, enter BioPharma-Reporter.com's...
Richard the III was blond, blue-eyed and may owe a substantial parking fine based on new genetic research that solves a 529-year old missing persons case.
There is no evidence that Ebola arrived on Earth from the stars, say a number of virologists, debunking media speculation that viruses had their origins in the Milky Way.
Ramesses II didn't need Enbrel, Remicade, Humira or any other TNFα blocker according to a study that rejects the idea the pharaoh was plagued, all puns intended, by ankylosing spondylitis.
A newly discovered virus which infects intestinal bacteria might be a cause of obesity, but could increasing interest in bacteriophages drive new personalised medicines and alternatives to antibiotics?
For live vaccine manufacturers working to extend shelf-life, the discovery that 60-year old smallpox virus found at a US Food and Drug Administration (FDA) lab could still be viable will be as galling as it is worrying.
Shark antibodies survive in urea concentrations that would denature other proteins thanks to a newly discovered structure that scientists say could be used to make therapeutic mAbs more robust.
A government funded bioprocessing institute is helping to drive biopharma investment and retrain workers in Ireland, and Biopharma-Reporter.com visited to find out what happens in this "flight simulator for biopharma manufacturing."
The US biosimilars market is becoming complicated even before the US FDA has issued manufacturers with clear guidance, thanks to a rapidly evolving patchwork of varying State substitution laws.
